The Taiwan-headquartered biotech said the FDA acknowledged receipt of its request for Vdelta2+ Gamma Delta T Cells, while JY BioMed is set to present preclinical glioblastoma data at WCP 2026.
verifying reliability
No specialized terms available for this topic.